CoChat

Comparative efficacy and acceptability of antidepressants in the long-term treatment of major depression: protocol for a systematic review and networkmeta-analysis

Open access

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

Introduction: Pharmacotherapy plays an important role in the treatment of major depression. At the initiation of antidepressant treatment, both improvement of symptoms in the short term and relapse prevention in the long term should be taken into account. However, there is insufficient evidence regarding the efficacy and the acceptability of continuation/maintenance treatments and the relative efficacy/acceptability of antidepressants. Objective: We will conduct a pairwise meta-analysis and a network meta-analysis (NMA) to examine the relative efficacy, tolerability and acceptability of antidepressants in the long-term treatment of major depression. Methods and analysis: We will include double-blind randomised controlled trials comparing any of the following antidepressants, which we included in our previous NMA of the acute treatment for major depression, with placebo or with another active drug for long-term treatment of major depression: agomelatine, amitriptyline, bupropion, citalopram, clomipramine, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, mirtazapine, nefazodone, paroxetine, reboxetine, sertraline, trazodone, venlafaxine, vilazodone and vortioxetine. Our primary outcomes will be sustained response and all-cause dropouts. We will include four types of designs that are used to investigate long-term treatment. We will conduct two main analyses. First, we will conduct a pairwise meta-analysis comparing all antidepressants versus placebo to investigate whether continuing antidepressants after achieving a positive response in the acute-phase treatment is beneficial and/or safe. Second, we will conduct an NMA to examine the comparative efficacy and acceptability of the drugs. We will use a novel approach that will combine the results of acute-phase treatment NMA with long-term treatment studies to include all related designs in the NMA. We will ensure the validity of combining different designs and our new approach by checking the distribution of important effect modifiers and consistency of network. Ethics and dissemination: This study did not require ethical approval. We will disseminate our findings by publishing results in a peer-reviewed journal. PROSPERO registration number: CRD42018114561; Pre-results.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjopen-2018-027574

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Different study designs for long-term treatment trials in a major depressive disorder.
Figure 1 Different study designs for long-term treatment trials in a major depressive disorder.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 33

Metadata

Authors
Shinohara, K., Efthimiou, O., Ostinelli, E. G., Tomlinson, A., Geddes, J. R., Nierenberg, A. A., Ruhe, H. G., Furukawa, T. A., & Cipriani, A.
Affiliations
  • Kyoto University (JP)
  • University of Bern (CH)
  • University of Milan (IT)
  • University of Oxford (GB)
  • Oxford Health NHS Foundation Trust (GB)
  • Massachusetts General Hospital (US)
  • Department of Psychiatry, Radboud University, Nijmegen, the Netherlands
Corresponding author
Shinohara, Kiyomi
Venue
BMJ Open
Publisher
BMJ
Published
2019-05-17
Volume
9
Issue
5
Pages
e027574
ISSN
2044-6055 (ISSN-L)
OpenAlex
W2944979889
Cited by
27
References
47
Citations by year
2025: 4 · 2024: 3 · 2023: 2 · 2022: 3 · 2021: 6 · 2020: 8 · 2019: 1
FWCI
0.58
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • BMJ Open (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (acceptedVersion)
  • Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc)
  • Radboud Repository (Radboud University) (submittedVersion, cc-by-nc-sa)
  • BORIS (University Library Bern) (submittedVersion, cc-by-nc)
  • Kyoto University Research Information Repository (Kyoto University) (submittedVersion, cc-by-nc)
  • Radboud Repository (Radboud University) (submittedVersion)
  • Open Access CRIS of the University of Bern
Funders
  • National Institute for Health Research (NIHR) Oxford Health Biomedical Research Centre
  • NIHR Research Professorship
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
Keywords
major depressive disorder, antidepressants, long-term maintenance therapy, continuation treatment, relapse prevention, sustained response, treatment discontinuation, tolerability, acceptability, drug efficacy comparison, network meta-analysis
MeSH terms
Network Meta-Analysis as Topic, Systematic Reviews as Topic, Antidepressive Agents, Major Depressive Disorder, Humans, Research Design

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparative efficacy and acceptability of antidepressants in the long-term treatment of major depression: protocol for a systematic review and networkmeta-analysis. https://app.cochat.ai/papers/10.1136/bmjopen-2018-027574
The paper
Shinohara, K., Efthimiou, O., Ostinelli, E. G., Tomlinson, A., Geddes, J. R., Nierenberg, A. A., Ruhe, H. G., Furukawa, T. A., & Cipriani, A. (2019). Comparative efficacy and acceptability of antidepressants in the long-term treatment of major depression: protocol for a systematic review and networkmeta-analysis. BMJ Open. https://doi.org/10.1136/bmjopen-2018-027574

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.